190P - Measurement of molecular biomarkers to predict tumor response in estrogen receptor positive breast cancer after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy

Abstract

Dose-dense (biweekly) paclitaxel/carboplatin(PC) as neoadjuvant Chemotherapy (NCT) for operable breast cancer is feasible and efficient. This study was to analysis the relationship between the molecular biomarkers and tumor response in estrogen receptor(ER) positive breast cancer. 84 ER-positive breast cancer patients treated with Dose-dense (biweekly) paclitaxel/carboplatin NCT were analyzed for expression of progesrone receptor (PgR), Tau, ki67, HER2, Bcl-2 by immunohistochemistry (IHC), these data were used to test whether these biomarkers can predict tumor response. The primary endpoint was a pathologically complete response (pCR). The second endpoint was the change in tumor size between pre and post NCT. Univariate analysis showed that HER2 positive (53.85% vs 8.62%, p < 0.01,Tau negative (40.91% vs 16.13%,p = 0.017, BCL-2 negative (48.15% vs 10.53%, p < 0.01) expression were associated with higher pCR rate. Multivariate analysis revealed that HER2 (OR: 8.116; 95%CI: 1.931-34.115; p = 0.04), BCL-2(OR: 0.176; 95%CI: 0.041-0.746; p = 0.018) were independent pCR predictive biomarkers. Tumor size was significant reduced in HER2 positive (p = 0.001, high-level ki67 (p = 0.007, Tau negative (p = 0.002, BCL-2 negative (p = 0.008) breast cancer. This study investigates the value of traditional biological markers, Bcl-2 and Tau in ER-positive patients treated with dose-dense (biweekly) paclitaxel/carboplatin NCT.